Intraocular pressure-lowering combination therapies with prostaglandin analogues

Drugs

Volumn 72, Issue 10, 2012, Pages 1355-1371

  Aptel, Florent ^a,b   Chiquet, Christophe ^a,b   Romanet, Jean Paul ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antiglaucomas; Apraclonidine; Bimatoprost; Bimatoprosttimolol; Brimonidine; Brinzolamide; Brinzolamidetravoprost; Dorzolamide; Fixed combinations; Glaucoma; Latanoprost; Latanoprosttimolol; Ocular hypertension; Prostaglandin F2 alpha agonists; Tafluprost; Tafluprosttimolol; Timolol; Travoprost; Travoprosttimolol

Indexed keywords

BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PROSTAGLANDIN DERIVATIVE; SAFLOTAN; TAFLUPROST; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; GLAUCOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; MORNING DOSAGE; NONHUMAN; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; VISION;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBONIC ANHYDRASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS; TREATMENT OUTCOME;

EID: 84863220857     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11634460-000000000-00000     Document Type: Article

References (99)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004 May; 363 (9422): 1711-20 (Pubitemid 38670330)
2. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-93 (Pubitemid 26158268)
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 Jun; 120 (6): 701-13 (Pubitemid 34620348)
4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002 Oct; 120 (10): 1268-79 (Pubitemid 36105431)
5. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998 Oct; 126 (4): 487-97
6. Advanced Glaucoma Intervention Study. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000 Oct; 130 (4): 429-40
7. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005 Jul; 112 (7): 1177-85 (Pubitemid 40916921)
8. Stewart WC, Konstas AG, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008 Jul; 115 (7): 1117-22
9. Van der Valk R, Webers CA, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009 Dec; 62 (12): 1279-83
10. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: Editrice Dogma, 2008
11. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern-Guidelines. Primary openangle glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2010 [online]. Available from URL: http://www.aao.org/ppp [Accessed 2012 May 31]
12. Feiner L, Piltz-Seymour JR, Collaborative Initial Glaucoma Treatment Study. Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol 2003 Apr; 14 (2): 106-11 (Pubitemid 36584231)
13. Stewart WC, Konstas AG, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004 Dec; 20 (6): 461-9 (Pubitemid 39628492)
14. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008 Nov; 53 Suppl. 1: S57-68
15. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005 May; 112 (5): 863-8 (Pubitemid 40631506)
16. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007 Oct; 144 (4): 533-40
17. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005 Jun; 112 (6): 953-61 (Pubitemid 40797446)
18. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid study. Ophthalmology 2009 Feb; 116 (2): 191-9
19. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995 May-Jun; 26 (3): 233-6
20. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmolol 2010 Feb; 4: 1-9
21. Taylor SA, Galbraith SM, Mills RP. Causes of noncompliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 2002 Oct; 18 (5): 401-9 (Pubitemid 37420249)
22. Djafari F, Lesk MR, Harasymowycz PJ, et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma 2009 Mar; 18 (3): 238-43
23. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010 Jul; 29 (4): 312-34
24. Egorov E, Ropo A, Investigators. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol 2009Mar-Apr; 19 (2): 214-22
25. Bron AM, Denis P, Nordmann JP, et al. Additive IOPreducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand 2001 Jun; 79 (3): 289-93 (Pubitemid 32577316)
26. Bucci MG, Italian Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. J Glaucoma 1999 Feb; 8 (1): 24-30
27. Diestelhorst M, German Latanoprost Study Group. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2%t.i.d. in patients with open-angle glaucoma or ocular hypertension: a 6-month, randomized, multicenter study. Graefes Arch Clin Exp Ophthalmol 2000 May; 238 (5): 433-9 (Pubitemid 30342664)
28. Petounis A, Mylopoulos N, Kandarakis A, et al. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with openangle glaucoma or ocular hypertension: a randomized, openlabel, multicenter study in Greece. J Glaucoma 2001 Aug; 10 (4): 316-24 (Pubitemid 32781348)
29. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005 Aug; 140 (2): 242-50
30. Hommer A, Ganfort Investigators Group I. A doublemasked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007 Jan-Feb; 17 (1): 53-62 (Pubitemid 46580599)
31. Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol 2002 Aug; 47: 133-40
32. Webers CA, van der Valk R, Schouten JS, et al. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology 2007 Jan; 114 (1): 40-6 (Pubitemid 46014293)
33. Webers CA, Beckers HJ, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical b-blocker therapy: a systematic review and meta-analysis. Ophthalmology 2010 Nov; 117 (11): 2067-74
34. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002 Jun; 133 (6): 836-7 (Pubitemid 34580639)
35. Erdogan H, Toker MI, AriciMK, et al. Effect of latanoprost 0.005%and brimonidine 0.2%on intraocular pressure after phacoemulsification and intraocular lens implantation surgery. Jpn J Ophthalmol 2004 Nov-Dec; 48 (6): 600-1 (Pubitemid 40104632)
36. Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005 Apr; 112 (4): 603-8 (Pubitemid 41108860)
37. Tsukamoto H, Noma H, Mukai S, et al. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther 2005 Oct; 21 (5): 395-9 (Pubitemid 41541059)
38. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005 Apr; 21 (4): 503-8
39. Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther 2007 Mar-Apr; 24 (2): 302-9 (Pubitemid 46988373)
40. Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma 2007 Jun-Jul; 16 (4): 352-7 (Pubitemid 46945531)
41. Tamer C, Oksuz H. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Ophthalmic Res 2007; 39 (1): 24-31 (Pubitemid 46098881)
42. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008 May; 24 (5): 1435-42 (Pubitemid 351741577)
43. Ishikawa M, Yoshitomi T. Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients. Clin Ophthalmol 2009; 3: 493-500
44. Liu JH, Medeiros FA, Slight JR, et al. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 2009 Mar; 116 (3): 449-54
45. Nakamura Y, Ishikawa S, Nakamura Y, et al. 24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost. Clin Ophthalmol 2009;3: 395-400
46. Inoue K, Masumoto M, Wakakura M, et al. Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months. Clin Ophthalmol 2011; 5: 393-6
47. Li Yim JF, Montgomery DM. The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost. Curr Med Res Opin 2011 Aug; 27 (8): 1499-502
48. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1%compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 2009 Sep; 116 (9): 1719-24
49. Reis R, Queiroz CF, Santos LC, et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 2006 Apr; 28 (4): 552-9 (Pubitemid 43783448)
50. Hollo G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006 Nov-Dec; 16 (6): 816-23 (Pubitemid 46174396)
51. Feldman RM, Tanna AP, Gross RL, et al., Additivity Study Group. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 2007 Jul; 114 (7): 1248-54
52. Netland PA, Michael M, Rosner SA, et al. Brimonidine purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2003 Jan-Feb; 20 (1): 20-30 (Pubitemid 36554437)
53. Stankiewicz A, Wierzbowska J, Siemiatkowska A, et al. The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma. Br J Ophthalmol 2010 Oct; 94 (10): 1307-11
54. Stankiewicz A, Misiuk-Hojło M, Grabska-Liberek I, et al. Intraocular pressure and ocular hemodynamics in patients with primary open-angle glaucoma treated with the combination of morning dosing of bimatoprost and dorzolamide hydrochloride. Acta Ophthalmol 2011 Feb; 89 (1): e57-63
55. Higginbotham EJ, Hansen J, Davis EJ, et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin 2009 Oct; 25 (10): 2543-7
56. Schwartz GF, Pate VD, Burk C, et al. Patient persistency with topical glaucoma therapy is higher with fixed dose brimonidine/timolol than with two-bottle combinations [abstract no. 185; plus poster A408]. Association for Research in Vision and Ophthalmology; 2010 May 2-6; Fort Lauderdale (FL)
57. Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. Trans Am Ophthalmol Soc 2008; 106: 138-45
58. Rolando M, Brezzo V, Giordano G, et al. The effect of different benzalkonium chloride concentrations on human normal ocular surface. In: Van Bijsterveld O, Lemp M, Spinelli D, editors. The lacrimal system. Amsterdam, Berkely, Milano: Kugler Publications, 1991
59. Nuzzi R, Finazzo C, Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response. Int Ophthalmol 1998; 22 (1): 31-5 (Pubitemid 29083233)
60. Guenoun JM, Baudouin C, Rat P, et al. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005 Dec; 46 (12): 4594-9 (Pubitemid 44264559)
61. Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmol 2008 Jan; 145 (1): 106-13 (Pubitemid 350265763)
62. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001 Jun; 10 (3): 184-91 (Pubitemid 32553579)
63. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006 Jan; 124 (1): 12-9 (Pubitemid 43063883)
64. Brandt JD, Cantor LB, Katz LJ, et al., Ganfort Investigators Group II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008 Apr-May; 17 (3): 211-6
65. Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-fourhour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol 2010 Feb; 94 (2): 209-13
66. Palmberg P, Kim EE, Kwok KK, et al., for the Canada and United States Fixed combination Latanoprost/Timolol Study Gro. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol 2010 Jul-Aug; 20 (4): 708-18
67. Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1998 Aug; 236 (8): 577-81 (Pubitemid 28379334)
68. Higginbotham EJ, Feldman R, Stiles M, et al., Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002 Jul; 120 (7): 915-22 (Pubitemid 34755544)
69. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002 Nov; 240 (11): 893-9 (Pubitemid 36097111)
70. Olander K, Zimmerman TJ, Downes N, et al., Xalacom/Latanoprost Study Group. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther 2004 Oct; 26 (10): 1619-29 (Pubitemid 39643022)
71. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-fourhour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005 Jul; 123 (7): 898-902 (Pubitemid 41057985)
72. Magacho L, Reis R, Shetty RK, et al. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology 2006 Mar; 113 (3): 442-5
73. Konstas AG, Lake S, Economou AI, et al. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol 2006 Nov; 124 (11): 1553-7 (Pubitemid 44748727)
74. Konstas AG, Pikilidou MI, Tsironi S, et al. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr Eye Res 2009 May; 34 (5): 369-77
75. Higginbotham EJ, Olander KW, Kim EE, et al., United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol 2010 Feb; 128 (12): 165-72
76. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005 Jul; 140 (1): 1-7 (Pubitemid 41008083)
77. Konstas AG, Mikropoulos D, Haidich AB, et al. Twentyfour-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol 2009 Apr; 93 (4): 481-5
78. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol 2012 Jan-Feb; 22 (1): 5-18
79. Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004 Feb; 88 (2): 199-203 (Pubitemid 38142086)
80. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005 Oct; 14 (5): 392-9 (Pubitemid 41383334)
81. Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006 Jan; 113 (1): 70-6 (Pubitemid 43021730)
82. Gross RL, Sullivan EK, Wells DT, et al. Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%. Clin Ophthalmol 2007 Sep; 1 (3): 317-22
83. Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in openangle glaucoma patients. Eye 2009 Apr; 23 (4): 810-8
84. Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol 2009 Jan-Feb; 19 (1): 66-71
85. Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 2007 May; 23 (5): 1025-32 (Pubitemid 46799584)
86. Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007 Mar-Apr; 17 (2): 183-90 (Pubitemid 46918103)
87. Centofanti M, Oddone F, Gandolfi S, et al. Comparing prostaglandin analogues plus timolol fixed combinations for the treatment of open angle glaucoma: the Glaucoma Randomized European Assessment Trial. Am J Ophthalmol 2010 Oct; 150 (4): 575-80
88. Rigollet JP, Ondategui JA, Pasto A, et al. Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate. Clin Ophthalmol 2011; 5: 187-91
89. Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin 2011 Oct; 27 (10): 1949-58
90. Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004 Feb; 111 (2): 276-82 (Pubitemid 38183227)
91. Konstas AG, Kozobolis VP, Lallos N, et al. (Pubitemid 40089997)
92. Martinez A, Sanchez M. (Pubitemid 46587859)
93. Konstas AG, Mikropoulos D, Dimopoulos AT, et al. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol 2008 Nov; 92 (11): 1498-502
94. Cvenkel B, Stewart JA, Nelson LA, et al. Dorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Curr Eye Res 2008 Feb; 33 (2): 163-8 (Pubitemid 351302198)
95. Pajic B, Pajic-Eggspuehler B, Hafliger IO. Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma. Curr Med Res Opin 2010 Sep; 26 (9): 2213-9
96. Miglior S, Grunden JW, Kwok K, Xalacom/Cosopt European Study Group. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye 2010 Jul; 24 (7): 1234-42
97. Teus MA, Miglior S, Laganovska G, et al. Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2009; 3: 629-36
98. Jothi R, Ismail AM, Senthamarai R, et al. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. Indian J Pharmacol 2010 Dec; 42 (6): 362-5
99. Liesegang TJ, Skuta GL, Cantor LB, et al. 2003-2004 Basic and clinical science course (BCSC) section 10: glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2003